Table 2.

Helicobacter pylori Eradication Rates for Tailored Therapy

Analysis	Eradication rates of tailored therapy by genotypic clarithromoycin resistance test
	Clarithromycin-sensitive		Clarithromycin-resistant
	14-Day CTT		14-Day BQT	14-Day MIT	p-value*
ITT analysis	486/581 (83.6)		82/102 (80.4)	69/99 (69.7)	0.079
PP analysis	486/533 (91.2)		77/81 (95.1)	68/89 (76.4)	0.001
Including rescue therapy	506/518 (97.7)		80/81 (98.8)	79/84 (94.0)	0.064

Data are presented as the number/number (%).

CTT, clarithromycin-based triple therapy; BQT, bismuth-based quadruple therapy; MIT, metronidazole-intensified triple therapy; ITT, intention-to-treat; PP, per-protocol.

*p-value indicates comparison between the BQT and MIT groups.